Author: Nichols Martin|| Date Published: June 10, 2021
Army Contracting Command has awarded Merck (NYSE: MRK) a one-year, $1.2 billion contract to deliver nearly 1.7 million courses of molnupiravir, an investigational oral antiviral agent intended to support the treatment of COVID-19 patients.
The Department of Defense said Wednesday the full contract amount was obligated on the firm-fixed-price contract using Coronavirus Aid, Relief and Economic Security Act funds.
Molnupiravir, also known as MK-4482, is undergoing a late-stage clinical trial, dubbed MOVe-OUT. Merck secured the contract through an online solicitation and will deliver the antiviral drug to the U.S. government once the Food and Drug Administration grants emergency use authorization.
Ridgeback Biotherapeutics works with Merck in the COVID-19 treatment development effort and the latter company expects more than 10 million courses of antiviral therapy to be available at the end of the year.
Chuck Brooks is the president of Brooks Consulting International and one of Executive Mosaic’s GovCon Experts. Most people associate the Department of…
CGI Federal has been tapped to continue supporting GSA’s financial systems environment The Momentum-as-a-Service model bundles software licensing, hosting and…
Helton will oversee infrastructure modernization, facilities, environmental health and safety, and security at the shipyard Helton arrives from HII’s Ingalls…
